Browse TGFBR2

Summary
SymbolTGFBR2
Nametransforming growth factor, beta receptor II (70/80kDa)
Aliases MFS2; transforming growth factor, beta receptor II (70-80kD); AAT3; FAA3; LDS1B; LDS2; LDS2B; RIIC; TAAD2; T ......
Chromosomal Location3p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Membrane raft
Domain PF08917 Transforming growth factor beta receptor 2 ectodomain
PF07714 Protein tyrosine kinase
Function

Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001525 angiogenesis
GO:0001569 patterning of blood vessels
GO:0001570 vasculogenesis
GO:0001654 eye development
GO:0001666 response to hypoxia
GO:0001667 ameboidal-type cell migration
GO:0001701 in utero embryonic development
GO:0001763 morphogenesis of a branching structure
GO:0001773 myeloid dendritic cell activation
GO:0001837 epithelial to mesenchymal transition
GO:0001865 NK T cell differentiation
GO:0001947 heart looping
GO:0002053 positive regulation of mesenchymal cell proliferation
GO:0002062 chondrocyte differentiation
GO:0002063 chondrocyte development
GO:0002088 lens development in camera-type eye
GO:0002274 myeloid leukocyte activation
GO:0002507 tolerance induction
GO:0002513 tolerance induction to self antigen
GO:0002514 B cell tolerance induction
GO:0002517 T cell tolerance induction
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002643 regulation of tolerance induction
GO:0002645 positive regulation of tolerance induction
GO:0002649 regulation of tolerance induction to self antigen
GO:0002651 positive regulation of tolerance induction to self antigen
GO:0002661 regulation of B cell tolerance induction
GO:0002663 positive regulation of B cell tolerance induction
GO:0002664 regulation of T cell tolerance induction
GO:0002666 positive regulation of T cell tolerance induction
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0003007 heart morphogenesis
GO:0003143 embryonic heart tube morphogenesis
GO:0003148 outflow tract septum morphogenesis
GO:0003149 membranous septum morphogenesis
GO:0003151 outflow tract morphogenesis
GO:0003170 heart valve development
GO:0003171 atrioventricular valve development
GO:0003175 tricuspid valve development
GO:0003179 heart valve morphogenesis
GO:0003181 atrioventricular valve morphogenesis
GO:0003186 tricuspid valve morphogenesis
GO:0003197 endocardial cushion development
GO:0003198 epithelial to mesenchymal transition involved in endocardial cushion formation
GO:0003203 endocardial cushion morphogenesis
GO:0003205 cardiac chamber development
GO:0003206 cardiac chamber morphogenesis
GO:0003208 cardiac ventricle morphogenesis
GO:0003214 cardiac left ventricle morphogenesis
GO:0003231 cardiac ventricle development
GO:0003272 endocardial cushion formation
GO:0003274 endocardial cushion fusion
GO:0003279 cardiac septum development
GO:0003281 ventricular septum development
GO:0003413 chondrocyte differentiation involved in endochondral bone morphogenesis
GO:0003415 chondrocyte hypertrophy
GO:0003416 endochondral bone growth
GO:0003417 growth plate cartilage development
GO:0003418 growth plate cartilage chondrocyte differentiation
GO:0003430 growth plate cartilage chondrocyte growth
GO:0003431 growth plate cartilage chondrocyte development
GO:0003433 chondrocyte development involved in endochondral bone morphogenesis
GO:0006898 receptor-mediated endocytosis
GO:0007159 leukocyte cell-cell adhesion
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007182 common-partner SMAD protein phosphorylation
GO:0007219 Notch signaling pathway
GO:0007224 smoothened signaling pathway
GO:0007368 determination of left/right symmetry
GO:0007369 gastrulation
GO:0007389 pattern specification process
GO:0007423 sensory organ development
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0007565 female pregnancy
GO:0007566 embryo implantation
GO:0007568 aging
GO:0007584 response to nutrient
GO:0009612 response to mechanical stimulus
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0009799 specification of symmetry
GO:0009855 determination of bilateral symmetry
GO:0009991 response to extracellular stimulus
GO:0010463 mesenchymal cell proliferation
GO:0010464 regulation of mesenchymal cell proliferation
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010634 positive regulation of epithelial cell migration
GO:0010717 regulation of epithelial to mesenchymal transition
GO:0010718 positive regulation of epithelial to mesenchymal transition
GO:0014706 striated muscle tissue development
GO:0014855 striated muscle cell proliferation
GO:0016049 cell growth
GO:0016202 regulation of striated muscle tissue development
GO:0017015 regulation of transforming growth factor beta receptor signaling pathway
GO:0018105 peptidyl-serine phosphorylation
GO:0018107 peptidyl-threonine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0018210 peptidyl-threonine modification
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0022612 gland morphogenesis
GO:0030098 lymphocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030217 T cell differentiation
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0030335 positive regulation of cell migration
GO:0030512 negative regulation of transforming growth factor beta receptor signaling pathway
GO:0030879 mammary gland development
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0031667 response to nutrient levels
GO:0032147 activation of protein kinase activity
GO:0033002 muscle cell proliferation
GO:0033674 positive regulation of kinase activity
GO:0034284 response to monosaccharide
GO:0035050 embryonic heart tube development
GO:0035162 embryonic hemopoiesis
GO:0035239 tube morphogenesis
GO:0035265 organ growth
GO:0036293 response to decreased oxygen levels
GO:0036314 response to sterol
GO:0040017 positive regulation of locomotion
GO:0042110 T cell activation
GO:0042246 tissue regeneration
GO:0042493 response to drug
GO:0043010 camera-type eye development
GO:0043011 myeloid dendritic cell differentiation
GO:0043403 skeletal muscle tissue regeneration
GO:0043415 positive regulation of skeletal muscle tissue regeneration
GO:0043416 regulation of skeletal muscle tissue regeneration
GO:0043627 response to estrogen
GO:0044706 multi-multicellular organism process
GO:0045580 regulation of T cell differentiation
GO:0045582 positive regulation of T cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045621 positive regulation of lymphocyte differentiation
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045785 positive regulation of cell adhesion
GO:0045843 negative regulation of striated muscle tissue development
GO:0045860 positive regulation of protein kinase activity
GO:0045926 negative regulation of growth
GO:0045927 positive regulation of growth
GO:0046620 regulation of organ growth
GO:0046621 negative regulation of organ growth
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046635 positive regulation of alpha-beta T cell activation
GO:0046637 regulation of alpha-beta T cell differentiation
GO:0046638 positive regulation of alpha-beta T cell differentiation
GO:0048514 blood vessel morphogenesis
GO:0048545 response to steroid hormone
GO:0048562 embryonic organ morphogenesis
GO:0048565 digestive tract development
GO:0048568 embryonic organ development
GO:0048588 developmental cell growth
GO:0048634 regulation of muscle organ development
GO:0048635 negative regulation of muscle organ development
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0048640 negative regulation of developmental growth
GO:0048645 animal organ formation
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0048701 embryonic cranial skeleton morphogenesis
GO:0048704 embryonic skeletal system morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0048706 embryonic skeletal system development
GO:0048732 gland development
GO:0048738 cardiac muscle tissue development
GO:0048754 branching morphogenesis of an epithelial tube
GO:0048762 mesenchymal cell differentiation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051136 regulation of NK T cell differentiation
GO:0051138 positive regulation of NK T cell differentiation
GO:0051216 cartilage development
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051272 positive regulation of cellular component movement
GO:0055017 cardiac muscle tissue growth
GO:0055021 regulation of cardiac muscle tissue growth
GO:0055022 negative regulation of cardiac muscle tissue growth
GO:0055024 regulation of cardiac muscle tissue development
GO:0055026 negative regulation of cardiac muscle tissue development
GO:0055123 digestive system development
GO:0060021 palate development
GO:0060038 cardiac muscle cell proliferation
GO:0060043 regulation of cardiac muscle cell proliferation
GO:0060044 negative regulation of cardiac muscle cell proliferation
GO:0060317 cardiac epithelial to mesenchymal transition
GO:0060348 bone development
GO:0060349 bone morphogenesis
GO:0060350 endochondral bone morphogenesis
GO:0060351 cartilage development involved in endochondral bone morphogenesis
GO:0060389 pathway-restricted SMAD protein phosphorylation
GO:0060411 cardiac septum morphogenesis
GO:0060412 ventricular septum morphogenesis
GO:0060419 heart growth
GO:0060420 regulation of heart growth
GO:0060425 lung morphogenesis
GO:0060433 bronchus development
GO:0060434 bronchus morphogenesis
GO:0060438 trachea development
GO:0060439 trachea morphogenesis
GO:0060440 trachea formation
GO:0060443 mammary gland morphogenesis
GO:0060462 lung lobe development
GO:0060463 lung lobe morphogenesis
GO:0060485 mesenchyme development
GO:0060537 muscle tissue development
GO:0060541 respiratory system development
GO:0060560 developmental growth involved in morphogenesis
GO:0060562 epithelial tube morphogenesis
GO:0061041 regulation of wound healing
GO:0061117 negative regulation of heart growth
GO:0061138 morphogenesis of a branching epithelium
GO:0061343 cell adhesion involved in heart morphogenesis
GO:0061371 determination of heart left/right asymmetry
GO:0061448 connective tissue development
GO:0070482 response to oxygen levels
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070723 response to cholesterol
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071593 lymphocyte aggregation
GO:0072132 mesenchyme morphogenesis
GO:0072593 reactive oxygen species metabolic process
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090101 negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090288 negative regulation of cellular response to growth factor stimulus
GO:0090303 positive regulation of wound healing
GO:0097028 dendritic cell differentiation
GO:0097305 response to alcohol
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
GO:0098868 bone growth
GO:1901342 regulation of vasculature development
GO:1901861 regulation of muscle tissue development
GO:1901862 negative regulation of muscle tissue development
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903034 regulation of response to wounding
GO:1903036 positive regulation of response to wounding
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:1903844 regulation of cellular response to transforming growth factor beta stimulus
GO:1903845 negative regulation of cellular response to transforming growth factor beta stimulus
GO:1904018 positive regulation of vasculature development
GO:1904019 epithelial cell apoptotic process
GO:1904888 cranial skeletal system development
GO:1905005 regulation of epithelial to mesenchymal transition involved in endocardial cushion formation
GO:1905007 positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation
GO:1990086 lens fiber cell apoptotic process
GO:2000027 regulation of organ morphogenesis
GO:2000147 positive regulation of cell motility
GO:2000377 regulation of reactive oxygen species metabolic process
GO:2000379 positive regulation of reactive oxygen species metabolic process
GO:2000826 regulation of heart morphogenesis
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004675 transmembrane receptor protein serine/threonine kinase activity
GO:0004702 receptor signaling protein serine/threonine kinase activity
GO:0005024 transforming growth factor beta-activated receptor activity
GO:0005026 transforming growth factor beta receptor activity, type II
GO:0005057 receptor signaling protein activity
GO:0005126 cytokine receptor binding
GO:0005160 transforming growth factor beta receptor binding
GO:0005539 glycosaminoglycan binding
GO:0019199 transmembrane receptor protein kinase activity
GO:0019838 growth factor binding
GO:0019955 cytokine binding
GO:0031435 mitogen-activated protein kinase kinase kinase binding
GO:0034713 type I transforming growth factor beta receptor binding
GO:0046332 SMAD binding
GO:0050431 transforming growth factor beta binding
Cellular Component GO:0005901 caveola
GO:0009897 external side of plasma membrane
GO:0043235 receptor complex
GO:0044853 plasma membrane raft
GO:0045121 membrane raft
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:0070022 transforming growth factor beta receptor homodimeric complex
GO:0098552 side of membrane
GO:0098589 membrane region
GO:0098802 plasma membrane receptor complex
GO:0098857 membrane microdomain
GO:1902554 serine/threonine protein kinase complex
GO:1902911 protein kinase complex
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04060 Cytokine-cytokine receptor interaction
hsa04068 FoxO signaling pathway
hsa04144 Endocytosis
hsa04350 TGF-beta signaling pathway
hsa04380 Osteoclast differentiation
hsa04390 Hippo signaling pathway
hsa04520 Adherens junction
Reactome R-HSA-5688426: Deubiquitination
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-2173788: Downregulation of TGF-beta receptor signaling
R-HSA-3304349: Loss of Function of SMAD2/3 in Cancer
R-HSA-3656534: Loss of Function of TGFBR1 in Cancer
R-HSA-3642278: Loss of Function of TGFBR2 in Cancer
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-3315487: SMAD2/3 MH2 Domain Mutants in Cancer
R-HSA-3304356: SMAD2/3 Phosphorylation Motif Mutants in Cancer
R-HSA-162582: Signal Transduction
R-HSA-170834: Signaling by TGF-beta Receptor Complex
R-HSA-3304351: Signaling by TGF-beta Receptor Complex in Cancer
R-HSA-2173789: TGF-beta receptor signaling activates SMADs
R-HSA-2173791: TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
R-HSA-3656532: TGFBR1 KD Mutants in Cancer
R-HSA-3656535: TGFBR1 LBD Mutants in Cancer
R-HSA-3645790: TGFBR2 Kinase Domain Mutants in Cancer
R-HSA-3642279: TGFBR2 MSI Frameshift Mutants in Cancer
R-HSA-5689603: UCH proteinases
Summary
SymbolTGFBR2
Nametransforming growth factor, beta receptor II (70/80kDa)
Aliases MFS2; transforming growth factor, beta receptor II (70-80kD); AAT3; FAA3; LDS1B; LDS2; LDS2B; RIIC; TAAD2; T ......
Chromosomal Location3p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TGFBR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TGFBR2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
17684491GlioblastomaInhibit immunityWe developed plasmid-transcribed small hairpin RNAs (shRNAs) to downregulate the TGF-beta type II receptor (TbetaIIR) expression, which effectively inhibited cytokine-induced signaling pathways and transcriptional responses in transiently transfected human glioblastoma cells. Silencing of TbetaIIR abolished TGF-beta-induced glioblastoma invasiveness and migratory responses in vitro. Moreover, tumorigenicity of glioblastoma cells stably expressing TbetaIIR shRNAs in nude mice was reduced by 50%.
21972292MelanomaInhibit immunityIn accordance with previous findings,44,45 we found that miR-17 inhibits TGF- signaling through targeting TGF RII. Biochemically, the reduction of either CREB1 or TGF RII is not dramatic, but the impacts from these moderate adjustments on T-cell function are not negligible.
Summary
SymbolTGFBR2
Nametransforming growth factor, beta receptor II (70/80kDa)
Aliases MFS2; transforming growth factor, beta receptor II (70-80kD); AAT3; FAA3; LDS1B; LDS2; LDS2B; RIIC; TAAD2; T ......
Chromosomal Location3p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TGFBR2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTGFBR2
Nametransforming growth factor, beta receptor II (70/80kDa)
Aliases MFS2; transforming growth factor, beta receptor II (70-80kD); AAT3; FAA3; LDS1B; LDS2; LDS2B; RIIC; TAAD2; T ......
Chromosomal Location3p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TGFBR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3130.34
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1440.95
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4340.79
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2490.628
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3330.886
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9860.744
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3050.564
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3360.872
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2070.932
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6550.695
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.7120.489
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4253.47e-05
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TGFBR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.37.4-2.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.515.4-10.90.541
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTGFBR2
Nametransforming growth factor, beta receptor II (70/80kDa)
Aliases MFS2; transforming growth factor, beta receptor II (70-80kD); AAT3; FAA3; LDS1B; LDS2; LDS2B; RIIC; TAAD2; T ......
Chromosomal Location3p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TGFBR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTGFBR2
Nametransforming growth factor, beta receptor II (70/80kDa)
Aliases MFS2; transforming growth factor, beta receptor II (70-80kD); AAT3; FAA3; LDS1B; LDS2; LDS2B; RIIC; TAAD2; T ......
Chromosomal Location3p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TGFBR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TGFBR2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTGFBR2
Nametransforming growth factor, beta receptor II (70/80kDa)
Aliases MFS2; transforming growth factor, beta receptor II (70-80kD); AAT3; FAA3; LDS1B; LDS2; LDS2B; RIIC; TAAD2; T ......
Chromosomal Location3p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TGFBR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTGFBR2
Nametransforming growth factor, beta receptor II (70/80kDa)
Aliases MFS2; transforming growth factor, beta receptor II (70-80kD); AAT3; FAA3; LDS1B; LDS2; LDS2B; RIIC; TAAD2; T ......
Chromosomal Location3p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TGFBR2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTGFBR2
Nametransforming growth factor, beta receptor II (70/80kDa)
Aliases MFS2; transforming growth factor, beta receptor II (70-80kD); AAT3; FAA3; LDS1B; LDS2; LDS2B; RIIC; TAAD2; T ......
Chromosomal Location3p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TGFBR2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTGFBR2
Nametransforming growth factor, beta receptor II (70/80kDa)
Aliases MFS2; transforming growth factor, beta receptor II (70-80kD); AAT3; FAA3; LDS1B; LDS2; LDS2B; RIIC; TAAD2; T ......
Chromosomal Location3p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TGFBR2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TGFBR2.
ID Name Drug Type Targets #Targets
DB09462GlycerinSmall MoleculeADH1B, ARF1, GSTP1, HPGDS, ISYNA1, ITPR1, NAGA, PAEP, PAPSS1, PLA2 ......13